<DOC>
	<DOCNO>NCT01957956</DOCNO>
	<brief_summary>This pilot clinical trial study vaccine therapy temozolomide treat patient newly diagnose glioblastoma . Vaccines make person 's white blood cell mixed tumor protein may help body build effective immune response kill tumor cell . Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop divide . Giving vaccine therapy temozolomide may effective treatment glioblastoma .</brief_summary>
	<brief_title>Vaccine Therapy Temozolomide Treating Patients With Newly Diagnosed Glioblastoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine safety feasibility adjuvant temozolomide plus combined allogeneic tumor primary tumor culture lysate / autologous dendritic cell ( DC ) vaccination ( malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ) newly diagnose glioblastoma patient follow surgical debulking external beam radiation therapy concurrent temozolomide . SECONDARY OBJECTIVES : I . To document survival progression-free survival newly diagnose glioblastoma patient receive adjuvant temozolomide plus allogeneic tumor primary tumor culture lysate / autologous DC vaccination historical data . TERTIARY OBJECTIVES : I . Determine ability allogeneic tumor primary tumor culture lysate / autologous DC vaccine generate multiple tumor-associated antigen ( TAA ) -specific immune response newly diagnose glioblastoma multiforme ( GBM ) patient . II . Assess relationship ability tumor induce TAA-specific immune response evidence immunosuppression ( peripheral blood immunophenotyping flow cytometry ) follow allogeneic tumor primary tumor culture lysate / autologous DC vaccine newly diagnose GBM patient . III . Assess relationship efficacy endpoint ( survival , progression-free survival , tumor response ) tumor-associated antigen immune response follow combine autologous allogeneic tumor lysate / DC vaccination adjuvant temozolomide . IV . Assess relationship efficacy endpoint ( survival , progression-free survival , tumor response ) evidence immunosuppression baseline time combine autologous allogeneic tumor lysate / DC vaccination adjuvant temozolomide . OUTLINE : COURSE 1 : Patients receive temozolomide orally ( PO ) daily day 1-5 . COURSES 2-3 : Patients receive temozolomide PO daily day 1-5 malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine intradermally ( ID ) day 1 , 3 , 5 . COURSES 4-6 : Patients receive temozolomide PO daily day 1-5 malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID day 1 . COURSES 7-12 : Patients receive malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID day 1 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year every 6 month 3 year .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Willing capable undergoing apheresis collection mononuclear cell Histologically confirm GBM ( grade 4 astrocytoma ) NOTE : gliosarcomas grade 4 astrocytoma variant ( e.g. , giant cell ) may include , primitive neuroectodermal tumor ( PNET ) variant exclude ; grade 4 oligodendrogliomas oligoastrocytomas specifically exclude Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 , 2 Absolute neutrophil count ( ANC ) &gt; = 1500 / uL Platelets ( PLT ) &gt; = 100,000 / uL Hemoglobin ( HgB ) &gt; = 9.0 g/dL Total bilirubin = &lt; 1.5 x upper normal limit ( UNL ) Serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) = &lt; 3 x UNL Creatinine = &lt; 1 x UNL Negative pregnancy test do = &lt; 7 day prior registration , woman childbearing potential Ability understand willingness sign write informed consent Willing return Mayo Clinic Rochester followup Willing provide tissue blood sample mandatory correlative research purpose Fixed decrease dose corticosteroid ( corticosteroid ) &gt; = 7 day prior registration Completed standard external beam radiation temozolomide Achieved gross total subtotal resection time surgery Current prior treatment cancer immunotherapy and/or investigational agent Any follow Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception Comorbid systemic illness severe concurrent disease , judgment investigator , would make patient inappropriate entry study interfere significantly proper assessment safety toxicity prescribe regimen Immunocompromised patient ( relate use corticosteroid ) include patient know human immunodeficiency virus ( HIV ) , human Tcell lymphotropic virus ( HTLV ) , hepatitis B ( HepB ) , hepatitis C ( HepC ) positive Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement History malignancy include treat low grade glioma ; EXCEPTIONS : nonmelanotic skin cancer , carcinomainsitu cervix , low grade glioma never treat previously ; NOTE : history prior malignancy , must receive specific treatment cancer History myocardial infarction = &lt; 180 day ( 6 month ) , congestive heart failure require use ongoing maintenance therapy lifethreatening ventricular arrhythmia Active infection = &lt; 5 day prior registration fever &gt; 38 degree Celsius ( C ) day registration History tuberculosis positive purify protein derivative ( PPD ) test Inability unwillingness magnetic resonance imaging ( MRI ) scan perform ( e.g . cardiac pacemakerdependent )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>